Charles River Laboratories

Charles River Laboratories is a leading provider of drug discovery and preclinical research services to pharmaceutical and biotechnology companies, supplying research models and running safety and efficacy testing that underpin early-stage drug development. Its deep integration into the discovery pipeline makes it a critical partner for the life-sciences industry. The company has only recently begun paying a very small dividend, so it lacks any meaningful income history and the yield is negligible. This remains a growth-oriented holding whose returns depend on research-and-development spending by its customers, and the low score reflects the token payout together with the cyclicality of biopharma funding.